Does Kaiser Permanente Cover AndroGel?

How Kaiser Permanente's Formulary Works for Testosterone Gel

Kaiser Permanente runs one of the most tightly integrated HMO models in the United States, and that integration extends to drug coverage. Unlike commercial PPO plans that use a Pharmacy Benefit Manager's open formulary, Kaiser's regional plans maintain closed formularies developed internally by Kaiser's Pharmacy and Therapeutics (P&T) committees. Generic testosterone gel (testosterone gel 1% and testosterone gel 1.62%) sits on Tier 1 or Tier 2 across most Kaiser regional formularies. Brand-name AndroGel (AbbVie) occupies a non-preferred brand tier, which means Kaiser will not cover it until a member has first tried and either failed or been documented as intolerant to the generic equivalent.

The FDA approved AndroGel 1% in 2000 and AndroGel 1.62% in 2011, both for hypogonadism in adult males with confirmed low testosterone. The FDA labeling for both strengths is available at the FDA accessdata portal. Because the active molecule is identical between brand and generic, Kaiser's P&T committees treat the two as therapeutically equivalent for most patients, consistent with FDA substitution rules.

A Kaiser member who needs testosterone gel will typically receive a prescription for generic testosterone gel 1.62% written by a Kaiser-employed endocrinologist or urologist. The prescriber cannot be an outside provider because Kaiser's closed-system PA process routes through internal clinical reviewers. An out-of-network prescription for AndroGel will be denied at the pharmacy counter without exception in most Kaiser regions.

The American Urological Association's 2018 guideline on testosterone deficiency states that clinicians should confirm the diagnosis with two separate morning total testosterone measurements below the laboratory reference range before initiating therapy. AUA Testosterone Deficiency Guideline Most Kaiser regions use a cutoff of total testosterone <300 ng/dL, consistent with the Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, which recommends that "testosterone therapy should not be initiated unless serum testosterone concentration is unequivocally low on at least two occasions." Endocrine Society 2018 Guideline on Male Hypogonadism Meeting that lab threshold is the first requirement before any prior authorization can be submitted.

What the Clinical Evidence Says About Testosterone Gel

Kaiser's internal coverage decisions reflect the published evidence base, and that evidence base is significant. The Testosterone Trials (T-Trials), a coordinated set of seven double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2016, enrolled 788 men aged 65 or older with a total testosterone below 275 ng/dL and at least one symptom of hypogonadism. T-Trials NEJM 2016, PubMed Testosterone gel normalized serum testosterone in the treatment group and produced statistically significant improvements in sexual activity (mean Sexual Activity Questionnaire score increase of 2.64 vs. 0.48 for placebo, P<0.001), walking distance at 6 months, and bone mineral density at the lumbar spine after 12 months.

The T-Trials also documented a higher rate of cardiovascular-related findings in the testosterone arm, which is one reason Kaiser's P&T committees require cardiovascular risk stratification before approving TRT in men over 55. Specifically, the coronary artery calcium sub-trial found a greater increase in coronary artery plaque volume in testosterone-treated men (mean 41 mm³ vs. 15 mm³ for placebo). T-Trials coronary artery plaque sub-study, PubMed That finding informed the FDA's 2015 label update requiring a cardiovascular risk warning on all testosterone products. FDA 2015 testosterone safety communication

A 2023 randomized controlled trial, TRAVERSE (N=5,198 men with or at high risk for cardiovascular disease), found that testosterone therapy did not increase major adverse cardiovascular events compared to placebo over a median 33 months of follow-up (hazard ratio 0.96 to 95% CI 0.78, 1.17). TRAVERSE trial, PubMed That result has begun to shift prescriber confidence in TRT for men with stable cardiovascular disease, and some Kaiser regions have quietly updated their PA criteria to deprioritize cardiac history as a standalone exclusion criterion.

The Endocrine Society's position on testosterone formulations notes that transdermal gels produce more stable serum levels than intramuscular injections, with fewer peaks and troughs. Endocrine Society testosterone therapy review, PubMed Daily application of testosterone gel 1.62% at doses of 40.5 to 81 mg typically maintains serum total testosterone between 400 and 700 ng/dL in most treated men. AndroGel 1.62% prescribing information, FDA accessdata Generic testosterone gel at the same concentration is bioequivalent and will produce the same pharmacokinetic profile.

Kaiser Permanente Prior Authorization Criteria for AndroGel

Prior authorization for brand-name AndroGel at Kaiser is genuinely difficult to obtain, and most members will spend weeks going through the internal process before a decision is rendered. The PA criteria in most Kaiser regions require all of the following to be documented in the Kaiser electronic health record (Epic):

Lab documentation. Two fasting morning total testosterone measurements below 300 ng/dL, drawn at least one week apart, with the samples collected between 7 a.m. and 10 a.m. Free testosterone below 65 pg/mL may substitute for total testosterone if sex hormone-binding globulin (SHBG) is elevated above 50 nmol/L. SHBG and free testosterone measurement guidance, PubMed

Symptom documentation. At least three symptoms from the Androgen Deficiency in Aging Males (ADAM) questionnaire or equivalent, documented in the clinical note by the Kaiser prescriber. Symptoms must include at least one sexual symptom (decreased libido, erectile dysfunction, or reduced spontaneous erections).

Step therapy completion. The member must have a documented trial of at least 60 days of generic testosterone gel 1% or 1.62% at an adequate dose, plus documented clinical or laboratory failure. Failure is defined as either persistent symptoms with serum testosterone remaining below 400 ng/dL after 60 days, or a documented adverse reaction such as contact dermatitis that is specific to the inactive excipients in the generic formulation and not present with the brand.

Prescriber eligibility. The prescribing clinician must be a Kaiser-employed endocrinologist, urologist, or in some regions an internal medicine physician with documented training in men's health. Outside prescribers cannot submit Kaiser PA requests. Period.

Cardiovascular screening. Men 45 or older must have a cardiovascular risk assessment documented within the prior 12 months, consistent with ACC/AHA guidelines. ACC/AHA 2019 cardiovascular risk guideline, PubMed Men with a history of myocardial infarction, stroke, or thromboembolic event within the prior six months are typically excluded.

Hematocrit. Baseline hematocrit below 50% must be documented, consistent with the Endocrine Society's recommendation against initiating testosterone therapy in men with erythrocytosis (hematocrit above 54%). Endocrine Society 2018 guideline, PubMed

The PA approval window, if granted, is typically 12 months, after which re-authorization requires repeat lab confirmation and a clinical note documenting ongoing symptom response.

Step Therapy: What You Must Try Before Kaiser Will Consider AndroGel

Kaiser's step therapy protocol for testosterone gel is a single-step requirement. The member tries generic testosterone gel first. The step is considered complete either when the generic fails to achieve therapeutic testosterone levels after 60 days at an adequate titrated dose, when the patient documents a true formulation-specific intolerance, or when the prescriber documents a clinical reason why brand-specific inactive ingredients are necessary for the individual patient.

A generic-specific intolerance claim requires documentation in the medical record. A note that says "patient prefers brand" will not satisfy the step. The intolerance must be objective: a dermatology note confirming contact dermatitis with negative patch testing to the active ingredient but positive testing to a generic excipient, for example. Contact allergen patch testing methodology, PubMed That level of documentation is uncommon and requires a referral to Kaiser's dermatology department, which adds weeks to the timeline.

For most men, the practical path is to trial generic testosterone gel sincerely, titrate to at least the 81 mg/day dose equivalent, draw a serum testosterone at day 60, and document the result. If the serum testosterone remains below 400 ng/dL or symptoms persist with a level above 300 ng/dL but below 500 ng/dL, the prescriber can make a clinical case for brand-name AndroGel on the basis of pharmacokinetic inadequacy. Not all such cases will be approved, but documented lab failure provides the clearest pathway.

Generic testosterone gel 1.62% from manufacturers such as Perrigo or Teva is bioequivalent by FDA standards, and published pharmacokinetic data confirm comparable absorption profiles. FDA bioequivalence standards for topical gels, FDA The majority of men who trial the generic will achieve therapeutic levels and will not need the brand. That outcome is precisely what the step therapy protocol is designed to produce.

How to Appeal a Kaiser Permanente Denial of AndroGel

A denial letter from Kaiser arrives with a specific reason code and a deadline, typically 60 days for a standard appeal and 72 hours for an expedited appeal when the treating clinician certifies that a delay would seriously jeopardize the member's health. The appeal process has three stages.

Stage 1: Internal appeal. Submit a written appeal to Kaiser Member Services with the following attached: the original denial letter, a letter of medical necessity from the prescribing Kaiser clinician, copies of the two low testosterone lab results, documentation of the step therapy trial and its outcome, and any peer-reviewed literature supporting brand-specific therapy for the documented indication. The TRAVERSE trial data and the T-Trials data cited above are appropriate supporting references. TRAVERSE, PubMed Kaiser must respond to a standard internal appeal within 30 days in most states.

Stage 2: Independent Medical Review. If the internal appeal is denied, the member may file for an Independent Medical Review (IMR) or Independent Review Organization (IRO) review through the state insurance commissioner's office. In California, this is handled by the California Department of Managed Health Care (DMHC). In other Kaiser states, the equivalent agency applies. The IMR process uses a physician reviewer who has no affiliation with Kaiser. Approval rates for IMR on testosterone therapy denials are not published by Kaiser, but the DMHC reports an overall IMR overturn rate of approximately 28% for pharmacy disputes. DMHC IMR statistics, DMHC

Stage 3: External options. If the IMR upholds the denial, the member has the option of paying out of pocket, switching to a non-brand testosterone formulation covered by Kaiser (injectable testosterone cypionate is typically covered at Tier 1), or pursuing a complaint through the state insurance commissioner. Testosterone cypionate 200 mg/mL injection is available at most Kaiser pharmacies for under $20 per 10 mL vial with Kaiser coverage, making it the lowest-cost alternative for members who cannot obtain AndroGel coverage.

The framework below summarizes the four-stage decision tree a Kaiser member should follow when seeking AndroGel coverage. Your Kaiser clinician should document each step in Epic before submitting the PA.

Stage A. Confirm diagnosis: two morning total testosterone values <300 ng/dL plus at least three ADAM symptoms documented.

Stage B. Complete step therapy: 60-day trial of generic testosterone gel 1.62% titrated to 81 mg/day, with day-60 serum testosterone drawn.

Stage C. Submit PA: Kaiser-employed prescriber submits via Epic with all documentation above, including cardiovascular screening for men 45+.

Stage D. If denied, file internal appeal within 60 days, then escalate to state IMR if needed, with TRAVERSE and T-Trials citations attached.

Cost Comparison: Brand AndroGel vs. Covered Alternatives at Kaiser

Brand-name AndroGel carries a wholesale acquisition cost of approximately $510 per month for a 75 g tube of 1.62% gel (30-day supply). GoodRx AndroGel pricing data Without Kaiser coverage, the member pays that full amount or a negotiated cash price at a Kaiser pharmacy, which is unlikely to be discounted significantly below WAC for a non-formulary brand.

Generic testosterone gel 1.62% at a Kaiser pharmacy costs approximately $30 to $80 per month with Kaiser coverage at Tier 1, depending on the regional plan's copay structure. Injectable testosterone cypionate, also Tier 1 at Kaiser, costs under $20 per month at Kaiser pharmacies with coverage.

The cost differential between brand AndroGel ($510/month) and covered generic testosterone gel ($30, $80/month) is the central reason Kaiser's formulary is structured the way it is. The clinical evidence does not support a meaningful therapeutic difference between brand and generic for most men. FDA generic drug bioequivalence, FDA For the subset of men who genuinely fail generic therapy on pharmacokinetic grounds, the appeal pathway described above remains available.

The AbbVie myAbbVie Assist savings card, which can reduce out-of-pocket costs for commercially insured patients, explicitly excludes government-funded plans and HMO plans that prohibit co-pay card use, including Kaiser. Members enrolled in Kaiser Medicare Advantage plans are also excluded from manufacturer co-pay programs under federal anti-kickback provisions. CMS guidance on co-pay cards, CMS The savings card is not a viable cost-reduction tool for Kaiser members.

What Kaiser Covers as Alternatives to AndroGel

Kaiser's formulary offers several testosterone replacement options that are covered without the prior authorization burden that applies to brand AndroGel.

Testosterone cypionate injection (generic). This is the most accessible option at Kaiser. It is Tier 1, covered without PA for men with documented hypogonadism, and costs under $20 per month. The injection is given every 1 to 2 weeks by a Kaiser nurse or self-administered at home. Serum testosterone levels fluctuate more than with daily gel, but most men tolerate the regimen well. Testosterone cypionate pharmacokinetics, PubMed

Generic testosterone gel 1% or 1.62% (Perrigo, Teva, or equivalent). Covered at Tier 1 or Tier 2. PA is still required to confirm hypogonadism diagnosis, but the PA threshold is lower and approval is faster than for the brand. Bioequivalent to AndroGel by FDA standards.

Testosterone enanthate injection. Available in some Kaiser regions as an alternative to cypionate, with a similar pharmacokinetic profile and coverage tier. Testosterone enanthate pharmacokinetics, PubMed

Testosterone pellets (Testopel). Coverage varies significantly by Kaiser region. Some regional P&T committees cover Testopel with PA for men who cannot tolerate topical or injectable formulations. The pellets are implanted subcutaneously every 3 to 6 months and release testosterone steadily over that interval. Testosterone pellet pharmacokinetics, PubMed

Clomiphene citrate (off-label). Kaiser prescribers in some regions prescribe clomiphene citrate 25 to 50 mg every other day for men with secondary hypogonadism who wish to preserve fertility, as testosterone gel and injections suppress spermatogenesis. Clomiphene for secondary hypogonadism, PubMed Coverage for this off-label use varies, and a prescriber note documenting the fertility preservation rationale is required.

Does Kaiser Permanente Cover AndroGel for Weight Loss?

No. Kaiser will not cover AndroGel or any testosterone product for the purpose of weight loss. That indication is not FDA-approved. The FDA's approved labeling for testosterone gel products specifically limits use to adult males with hypogonadism defined by low serum testosterone and clinical symptoms. FDA testosterone labeling, FDA accessdata

Some men with obesity and low testosterone experience modest reductions in fat mass and modest gains in lean mass with testosterone therapy, but those effects are secondary to treatment of hypogonadism, not a standalone indication. A 2013 systematic review in the Journal of Clinical Endocrinology and Metabolism (covering 51 trials, N=3,016 men) found a mean reduction in fat mass of 1.6 kg with testosterone therapy vs. placebo, with a concurrent mean increase in lean mass of 1.6 kg. Testosterone and body composition meta-analysis, PubMed Kaiser's PA reviewers will not accept weight management as a primary indication for AndroGel coverage, and submitting a PA with weight loss as the stated goal will result in automatic denial.

Men seeking weight loss treatment at Kaiser should ask their Kaiser primary care physician about referral to Kaiser's obesity medicine program. GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound) are covered with PA for members meeting BMI criteria under Kaiser's current formulary, consistent with FDA approvals for chronic weight management. Semaglutide FDA approval for obesity, FDA The STEP-1 trial (N=1,961) showed 14.9% mean body weight reduction with semaglutide 2.4 mg at 68 weeks vs. 2.4% with placebo. STEP-1 trial, PubMed